B. Muldrew

Economic evaluation of Cytosponge®-trefoil factor 3 for Barrett esophagus: A cost-utility analysis of randomised controlled trial data

P. Sasieni, R. Fitzgerald, Stephen Morris, 2021, EClinicalMedicine.

A cross-sectional analysis of Facebook comments to study public perception of a new diagnostic test called the CytospongeTM

R. Fitzgerald, B. Muldrew, W. K. Tan, 2020 .

Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial

F. Markowetz, T. Bray, Shruti Singh, 2020, The Lancet.

Barrett’s oESophagus trial 3 (BEST3): study protocol for a randomised controlled trial comparing the Cytosponge-TFF3 test with usual care to facilitate the diagnosis of oesophageal pre-cancer in primary care patients with chronic acid reflux

S. Smith, P. Sasieni, M. O’Donovan, 2018, BMC Cancer.

A crosssectional analysis of Facebook comments to study public perception of a new diagnostic test called the Cytosponge.

R. Fitzgerald, B. Muldrew, Z. Khan, 2018, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.